Heather Parsons (@hthrparsons) 's Twitter Profile
Heather Parsons

@hthrparsons

Breast Cancer Physician-Scientist | @DanaFarber @HarvardMed #MBC #bcsm | Tweets are my own and not medical advice.

ID: 458539324

calendar_today08-01-2012 17:42:34

5 Tweet

574 Followers

420 Following

Gate.io (@gate_io) 's Twitter Profile Photo
Gate.io
@gate_io

5 hours ago

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358
The ASCO Post (@ascopost) 's Twitter Profile Photo
The ASCO Post
@ascopost

3 years ago

An Early Love of Science Led to a Career in Breast Cancer Research for Sara M. Tolaney, MD, MPH ascopost.com/issues/may-25-… #bcsm Dana-Farber

An Early Love of Science Led to a Career in Breast Cancer Research for Sara M. Tolaney, MD, MPH ascopost.com/issues/may-25-… #bcsm <a href="/DanaFarber/">Dana-Farber</a>
Mike Foote (@mikefootemd) 's Twitter Profile Photo
Mike Foote
@mikefootemd

3 years ago

Amazing oral presentation by Marla Lipsyc-Sharf, MD #ASCO22 Dana-Farber discussing high ROR with cDNA+ in HR+ high risk #breastcancer patients post surgery using highly sensitive (LOD VAF <0.04%) RaDaR test. Lead time: 1 year before radiographic recurrence. She is amazing!! #CHirP

Amazing oral presentation by <a href="/MarlaLipsycMD/">Marla Lipsyc-Sharf, MD</a> #ASCO22 <a href="/DanaFarber/">Dana-Farber</a> discussing high ROR with cDNA+ in HR+ high risk #breastcancer patients post surgery using highly sensitive (LOD VAF &lt;0.04%) RaDaR test. Lead time: 1 year before radiographic recurrence. She is amazing!! #CHirP
Heather Parsons (@hthrparsons) 's Twitter Profile Photo
Heather Parsons
@hthrparsons

3 years ago

Incredible job by Marla Lipsyc-Sharf, MD presenting our data today at #ASCO2022

Nancy Lin, MD (@nlinmd) 's Twitter Profile Photo
Nancy Lin, MD
@nlinmd

3 years ago

Stunning data from Destiny-Breast04. Most impressive PFS and OS data in the post-endocrine therapy setting in HR+ breast cancer I have ever seen. And eye opening OS benefit in TNBC subset.

Stunning data from Destiny-Breast04. Most impressive PFS and OS data in the post-endocrine therapy setting in HR+ breast cancer I have ever seen. And eye opening OS benefit in TNBC subset.